Cover Image
Market Research Report

Animal Pharm Pet Cancer 2019

Published by Animal Pharm Product code 854751
Published Content info 70 Pages
Delivery time: 1-2 business days
Price
Back to Top
Animal Pharm Pet Cancer 2019
Published: December 1, 2018 Content info: 70 Pages
Description

This important report reviews the diverse Research and Development (R&D) approaches currently employed in the rapidly developing global market for pet cancer products and services. It covers current trends in veterinary oncology, including regulatory strategies, chemotherapies, immunotherapies, diagnostics and complementary approaches.

Table of Contents
Product Code: 90432

Table of Contents

Contents

Executive Summary

Chapter 1: Introduction

  • 1.1. The Animal Health Industry
  • 1.2. The Companion Animal Sector
    • 1.2.1. Changes in Pet Ownership
      • Pet Ownership in the USA
      • Pet Ownership in Europe
    • 1.2.2. The Future of Companion Animal Health in Developed Markets
  • 1.3. Summary

Chapter 2: Pet Cancer - Factors Influencing the Market

  • 2.1. Overview
  • 2.2. Translation of Pet Cancer Research to Human Health
  • 2.3. Owner Perceptions of Cancer in their Pet
  • 2.4. Factors Influencing Owners Decisions in Relation to Chemotherapy
  • 2.5. Owners Concerns During Treatment of their Pet for Cancer
  • 2.6. Owner Perceptions of Radiotherapy
  • 2.7. Assessment of Quality of Life in Pets Receiving Cancer Treatment
  • 2.8. Vet Perceptions of Cancer Treatment of Pets
  • 2.9. Cancer Clinical Trials
  • 2.10. A Holistic Approach
  • 2.11. Supporting organisations

Chapter 3: The Animal Health Companies Cited in this Report

  • Overview
    • 3.1. AB Science
    • 3.2. Anivive Lifesciences
    • 3.3. Aratana Therapeutics
    • 3.4. ARK Animal Health
    • 3.5. Assisi Research Laboratories
    • 3.6. EirGen Pharma
    • 3.7. Elanco
    • 3.8. ELIAS Animal Health
    • 3.9. Jaguar (Animal) Health
    • 3.10. Karyopharm Therapeutics
    • 3.11. Man's Best Friends Therapeutics
    • 3.12. Merial/Boehringer Ingelheim
    • 3.13. Novavive
    • 3.14. Nuovo Biologics
    • 3.15. Ogenx Therapeutics Corporation
    • 3.16. Osamia Pharmaceutical
    • 3.17. PharmAust
    • 3.18. QBiotics
    • 3.19. Rhizen Pharmaceuticals
    • 3.20. Torigen Pharma
    • 3.21. Veiove Animal Health
    • 3.22. Vet DC
    • 3.23. Virbac
    • 3.24. Zoetis

Chapter 4: Regulation of Pet Cancer Products

  • 4.1. The United States (US) and European (EU) Regulatory Authorities
  • 4.2. Regulatory Guidance
  • 4.3. Availability of Pet Cancer Medicines and Vaccines
  • 4.4. Use of Unlicensed Medicinal Products

Chapter 5: Pet Cancer - Incidence

  • 5.1. Overview
  • 5.2. Pet Cancer Incidence
  • 5.3. Types and Locations of Pet Cancer
  • 5.4. Overall conclusion on the incidence and prevalence of cancer in pets

Chapter 6: Pet Cancer - Current Management Modalities for common tumours

  • 6.1. Mast Cell Tumours
  • 6.2. Mammary tumours
  • 6.3. Melanoma
  • 6.4. Lymphoma
  • 6.5. Injection site sarcoma/fibrosarcoma
  • 6.6. Squamous cell carcinoma
  • 6.7. Osteosarcoma

Chapter 7: Pet Cancer Pharmaceuticals

  • 7.1. Overview
  • 7.2. Palladia (Zoetis)
  • 7.3. Masivet (AB Science)
  • 7.4. Tanovea-CA1(VetDC)
  • 7.5. Paccal Vet-CA1(Osamia)
  • 7.6. Pet Cancer Pharmaceuticals in Development
    • Doxophos Vet (Osamia)
    • Tigilanol tiglate (QBiotics/Virbac)
    • Verdinexor (Anivive Lifesciences)
    • RC-2b geroxane (Ogenx Therapeutics Corporation)
    • Asparaginase (Assisi Research Laboratories)
    • Resiniferatoxin (ARK Animal Health)
    • SP-SAP: Substance P & Saporin (Veiove Animal Health)
    • RV1001, PI3Kδ inhibitor (Rhizen Pharmaceutical)
    • Chlorambucil (EirGen Pharma)
    • Canalevia (Jaguar Animal Health)
    • Dactinomycin (Assisi Research Laboratories)
  • 7.7. Other Potential Pet Cancer Products

Chapter 8: Pet Cancer Immunologicals

  • 8.1. Overview
  • 8.2. Oncept Canine Melanoma Vaccine DNA (Merial/Boehringer Ingelheim)
  • 8.3. Oncept IL-2(Merial/Boehringer Ingelheim)
  • 8.4. Immunocidin (Novavive)
  • 8.5. Pet Cancer Immunotherapies in Development
    • Osteosarcoma vaccine (Aratana Therapeutics)
    • Torigen Pharma
    • ELIAS Cancer Immunotherapy: ECI (Elias Animal Health)
    • Prophylactic Vaccine Project
    • Man's Best Friends Therapeutics (MBFT)
    • Summary
    • References

List of Figures

  • Figure 1: Percentage of European Households owning at least one cat or one dog
  • Figure 2: Pet age in human years
  • Figure 3: Holistic approach
  • Figure 4: Feline fibrosarcoma
  • Figure 5: Canine mammary tumour
  • Figure 6: Canine osteosarcoma
  • Figure 7: Mast Cell Tumours
  • Figure 8: Mammary Tumours
  • Figure 9: Canine Oral Melanoma
  • Figure 10: Feline Ocular Melanoma
  • Figure 11: Canine lymphoma
  • Figure 12: Feline lymphoma
  • Figure 13: Feline fibrosarcoma
  • Figure 14: Canine Squamous cell carcinoma
  • Figure 15: Feline Squamous cell carcinoma (extremities)
  • Figure 16: Feline Squamous cell carcinoma (oral)
  • Figure 17: Canine Osteosarcoma
  • Figure 18: Feline Osteosarcoma
  • Figure 19: Palladia
  • Figure 20: Masivet
  • Figure 21: Tanovea-CA1
  • Figure 22: Paccal Vet-CA-1
  • Figure 23: VET JET system
  • Figure 24: Oncept IL-2
  • Figure 25: Immunocidin

List of Tables

  • Table 1: Top ten dog and cat ownership countries in the EU in 2017
  • Table 2: Anti-cancer guidelines issued by the EMA and FDA CVM
  • Table 3: CVM designations with a canine cancer indication
  • Table 4: Summary of Veterinary Cancer Registries (Active and Dormant)
  • Table 5: Incidence of Canine Cancer in Developed Countries
  • Table 6: Incidence of Feline Cancer in Developed Countries
  • Table 7: Common Anatomical Locations for Canine Cancer
  • Table 8: Common Anatomical Locations for Feline Cancer
Back to Top